Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Status:
Completed
Trial end date:
2016-03-06
Target enrollment:
Participant gender:
Summary
This is the first human treatment with PRX-102, an enzyme being developed as a long-term
enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha
galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be
evaluated in this study of increasing doses. Patients will be treated with infusions every
two weeks for 12 months.